DANA-FARBER CANCER INSTITUTE, INC.;THE GENERAL HOSPITAL CORPORATION;THE BROAD INSTITUTE, INC.
发明人:
EDWARD B. HOLSON,FLORENCE FEVRIER WAGNER,JENNIFER Q. PAN,SIVARAMAN DANDAPANI,ANDREW GERMAIN,BENITO MUNOZ,PARTHA P. NAG,MICHEL WEIWER,MICHAEL C. LEWIS,STEPHEN J. HAGGARTY,JOSHUA A. BISHOP,KIMBERLY STEG
申请号:
PT13780300
公开号:
PT2909204T
申请日:
2013.10.11
申请国别(地区):
PT
年份:
2019
代理人:
摘要:
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3&bgr;) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.